Abstract Breast cancer cells frequently metastasize to bone. Despite the clinical ramifications, very little is understood about the fundamental mechanisms responsible for this phenomenon. While analyzing femur sections from mice that had been inoculated in the left ventricle of the heart with human metastatic MDA-MB-231 breast cancer cells, we saw a several fold increase in the number of megakaryocytes (MKs) in the bone marrow. We hypothesized that either MKs aid in the growth of cancer cells in the bone by preparing a niche for the metastases or that the increase resulted from the altered microenvironment of the marrow due to the presence of the cancer. MKs are the pre-cursors to platelets and normally represent a small portion of all bone marrow cells. However, they can increase exponentially under stressful conditions such as primary thrombocythemia and in chronic myelogenous leukemia. Platelets are known to interact with tumor cells to contribute to hematogenous metastasis and angiogenesis. Thrombocytosis, high platelet count, is a poor prognostic factor for breast cancer metastasis; and moreover, many cancer patients die from thromboembolisms. MKs also play a crucial role in bone metabolism and skeletal homeostasis. Objectives: to determine (1) if the increase in MKs precedes the growth of cancer cells in the bone; (2) the role that cancer cell-osteoblast/stromal interactions play in the increase in megakaryopoiesis. For aim 1, MK numbers in the femurs of athymic mice inoculated with MDA-MB-231-luc intracardially (metastasis) were compared with those inoculated in the mammary gland (no metastasis). Serum was assayed for key MK maturation factors thrombopoietin (TPO) and stromal-derived factor-1(SDF-1). There was on average a two-fold increase in MK numbers in the femurs of mice with metastasic disease. However, this increase was not found in mice with localized growth but no metastasis. The increase correlated with the increase in metastatic tumor burden. There was no increase in platelet count, SDF-1, or TPO even when MK numbers were high. We concluded that the cancer cells preceded the increase of MKs in the bone marrow in a xenograft model. A syngeneic model of Balb/c mice with 4T1.2 cancer cells that metastasize from the mammary gland and 67NR cells that do not are also being compared. Thus far we have found that femurs of mice carrying 4t1.2 cells for 30 days also showed an increase in the numbers of MKs. Finally, Balb/c mice lacking TPO and thus having low MKs will be tested for metastasis. This work was supported by the U.S. Army Medical Research and Materiel Command under W81XWH-10-1-0253. Citation Format: Walter Jackson, Andrea M. Mastro. The role of megakaryocytes in breast cancer metastasis to bone. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3936. doi:10.1158/1538-7445.AM2013-3936
Read full abstract